» Articles » PMID: 9307275

Mutations in PTEN Are Frequent in Endometrial Carcinoma but Rare in Other Common Gynecological Malignancies

Overview
Journal Cancer Res
Specialty Oncology
Date 1997 Oct 27
PMID 9307275
Citations 192
Authors
Affiliations
Soon will be listed here.
Abstract

Loss of heterozygosity of chromosome 10q has been reported in approximately 40% of endometrial carcinomas. PTEN, a candidate tumor suppressor gene located at chromosome 10q23.3, was recently identified and found to be homozygously deleted or mutated in several different types of human tumors. To determine if PTEN is a target of 10q loss of heterozygosity in carcinomas of the endometrium, we examined 32 primary endometrial carcinomas for mutations in PTEN. The tumors included the two major histopathological types of endometrial carcinoma: endometrioid (n = 26; 14 microsatellite instability (MI)-positive and 12 MI-negative) and serous (n = 6). Overall, mutations were detected in 50% of the endometrial carcinomas we analyzed. Mutations were present in 12 of 14 (86%) MI-positive and 4 of 12 (33%) MI-negative endometrioid tumors. Furthermore, mutations were found in all three histological grades of MI-positive endometrioid carcinoma. All six serous endometrial carcinomas lacked detectable mutations. To evaluate the role of PTEN in other common malignancies of the female genital tract, 12 serous ovarian carcinomas and 10 squamous cervical carcinomas were analyzed and were negative for mutations. Our results support PTEN as a tumor suppressor gene and suggest that mutations in PTEN play a significant role in the pathogenesis of the endometrioid type of endometrial carcinoma.

Citing Articles

Uterine organoids reveal insights into epithelial specification and plasticity in development and disease.

Rizo J, Ahmad V, Pru J, Winuthayanon S, Challa S, Kim T Proc Natl Acad Sci U S A. 2025; 122(5):e2422694122.

PMID: 39883834 PMC: 11804710. DOI: 10.1073/pnas.2422694122.


mTOR Pathway Inhibition, Anticancer Activity and In Silico Calculations of Novel Hydrazone Derivatives in Two- and Three-Dimensional Cultured Type 1 Endometrial Cancer Cells.

Bulbul M, Mermer A, Kolbasi B, Kocabas F, Kalender S, Kirectepe Aydin K Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770404 PMC: 11678851. DOI: 10.3390/ph17121562.


Endometriosis development in relation to hypoxia: a murine model study.

Hoffmann-Mlodzianowska M, Maksym R, Pucia K, Kuciak M, Mackiewicz A, Kieda C Mol Med. 2024; 30(1):195.

PMID: 39478503 PMC: 11526686. DOI: 10.1186/s10020-024-00973-x.


The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers.

Wang F, Zhou C, Zhu Y, Keshavarzi M Cell Biol Toxicol. 2024; 40(1):42.

PMID: 38836981 PMC: 11153289. DOI: 10.1007/s10565-024-09884-3.


In Vivo Intra-Uterine Delivery of TAT-Fused Cre Recombinase and CRISPR/Cas9 Editing System in Mice Unveil Histopathology of Pten/p53-Deficient Endometrial Cancers.

Navaridas R, Vidal-Sabanes M, Ruiz-Mitjana A, Altes G, Perramon-Guell A, Yeramian A Adv Sci (Weinh). 2023; 10(32):e2303134.

PMID: 37749866 PMC: 10646277. DOI: 10.1002/advs.202303134.